242 related articles for article (PubMed ID: 11314752)
1. Clinical application of 5alpha-reductase inhibitors.
Cilotti A; Danza G; Serio M
J Endocrinol Invest; 2001 Mar; 24(3):199-203. PubMed ID: 11314752
[TBL] [Abstract][Full Text] [Related]
2. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
Bartsch G; Rittmaster RS; Klocker H
Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
[TBL] [Abstract][Full Text] [Related]
3. [Dihydrotestosterone and the role of 5 alpha-reductase inhibitors in benign prostatic hyperplasia].
Bartsch G; Rittmaster RS; Klocker H
Urologe A; 2002 Sep; 41(5):412-24. PubMed ID: 12426858
[TBL] [Abstract][Full Text] [Related]
4. Prostatic expression of human 5alpha-reductase type 2 during finasteride therapy: a randomized, double-blind, placebo-controlled study.
Vaarala MH; Lukkarinen O; Marttila T; Kyllönen AP; Porvari KS; Vihko PT
World J Urol; 2000 Dec; 18(6):406-10. PubMed ID: 11204259
[TBL] [Abstract][Full Text] [Related]
5. Comparative study of human steroid 5alpha-reductase isoforms in prostate and female breast skin tissues: sensitivity to inhibition by finasteride and epristeride.
Ranjan M; Diffley P; Stephen G; Price D; Walton TJ; Newton RP
Life Sci; 2002 May; 71(2):115-26. PubMed ID: 12031682
[TBL] [Abstract][Full Text] [Related]
6. Finasteride: a clinical review.
Gormley GJ
Biomed Pharmacother; 1995; 49(7-8):319-24. PubMed ID: 8562856
[TBL] [Abstract][Full Text] [Related]
7. 5alpha-reductase activity in the prostate.
Steers WD
Urology; 2001 Dec; 58(6 Suppl 1):17-24; discussion 24. PubMed ID: 11750244
[TBL] [Abstract][Full Text] [Related]
8. The 5 alpha-reductase system and its inhibitors. Recent development and its perspective in treating androgen-dependent skin disorders.
Chen W; Zouboulis CC; Orfanos CE
Dermatology; 1996; 193(3):177-84. PubMed ID: 8944337
[TBL] [Abstract][Full Text] [Related]
9. [Significance of 5-alpha-reductase inhibitors in therapy of benign prostatic hyperplasia with mild to modern symptoms].
Wirth MP; Helke C; Froschermaier SE
Urologe A; 1997 Jan; 36(1):35-9. PubMed ID: 9123679
[TBL] [Abstract][Full Text] [Related]
10. [Finasteride: a new drug for the treatment of male hirsutism and androgenetic alopecia?].
Spinucci G; Pasquali R
Clin Ter; 1996 Jun; 147(6):305-15. PubMed ID: 8925640
[TBL] [Abstract][Full Text] [Related]
11. Selectivity of finasteride as an in vivo inhibitor of 5alpha-reductase isozyme enzymatic activity in the human prostate.
Span PN; Völler MC; Smals AG; Sweep FG; Schalken JA; Feneley MR; Kirby RS
J Urol; 1999 Jan; 161(1):332-7. PubMed ID: 10037433
[TBL] [Abstract][Full Text] [Related]
12. The clinical applications of five-alpha reductase inhibitors.
Loughlin KR
Can J Urol; 2021 Apr; 28(2):10584-10588. PubMed ID: 33872554
[TBL] [Abstract][Full Text] [Related]
13. Role of 5α-reductase inhibitors in androgen-stimulated skin disorders.
Azzouni F; Zeitouni N; Mohler J
J Drugs Dermatol; 2013 Feb; 12(2):e30-5. PubMed ID: 23377402
[TBL] [Abstract][Full Text] [Related]
14. Dihydrotestosterone and the prostate: the scientific rationale for 5alpha-reductase inhibitors in the treatment of benign prostatic hyperplasia.
Andriole G; Bruchovsky N; Chung LW; Matsumoto AM; Rittmaster R; Roehrborn C; Russell D; Tindall D
J Urol; 2004 Oct; 172(4 Pt 1):1399-403. PubMed ID: 15371854
[TBL] [Abstract][Full Text] [Related]
15. Inhibitors of 5alpha-reductase in the treatment of benign prostatic hyperplasia.
Tarter TH; Vaughan ED
Curr Pharm Des; 2006; 12(7):775-83. PubMed ID: 16515494
[TBL] [Abstract][Full Text] [Related]
16. 5alpha-reductase inhibitors/finasteride.
Stoner E
Prostate Suppl; 1996; 6():82-7. PubMed ID: 8630236
[TBL] [Abstract][Full Text] [Related]
17. Expression of basic fibroblast growth factor and its receptors FGFR1 and FGFR2 in human benign prostatic hyperplasia treated with finasteride.
Sáez C; González-Baena AC; Japón MA; Giráldez J; Segura DI; Rodríguez-Vallejo JM; González-Esteban J; Miranda G; Torrubia F
Prostate; 1999 Jul; 40(2):83-8. PubMed ID: 10386468
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the pharmacological effects of a novel selective androgen receptor modulator, the 5alpha-reductase inhibitor finasteride, and the antiandrogen hydroxyflutamide in intact rats: new approach for benign prostate hyperplasia.
Gao W; Kearbey JD; Nair VA; Chung K; Parlow AF; Miller DD; Dalton JT
Endocrinology; 2004 Dec; 145(12):5420-8. PubMed ID: 15308613
[TBL] [Abstract][Full Text] [Related]
19. Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know?
Traish AM; Melcangi RC; Bortolato M; Garcia-Segura LM; Zitzmann M
Rev Endocr Metab Disord; 2015 Sep; 16(3):177-98. PubMed ID: 26296373
[TBL] [Abstract][Full Text] [Related]
20. An overview on 5alpha-reductase inhibitors.
Aggarwal S; Thareja S; Verma A; Bhardwaj TR; Kumar M
Steroids; 2010 Feb; 75(2):109-53. PubMed ID: 19879888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]